Indeed, mutations at the palmitoylation site of oncogenic Kras4A (Kras4AG12D/C180S) significantly abrogate leukemogenesis, although these mutations still induce leukemia, albeit with a much longer latency [45]. The gene discussed is KRAS; the disease is leukemia.